交银国际发布研报称，百济神州(06160.HK)去年第四季泽布替尼销售额11亿美元(下同)，同比及按季分 别升38%及10%，美国销售额8.45亿，同比及按季分别升37%及14%。在1LCLL患者中，泽布在BTK品 类中的份额约占一半、在所有治疗药物中约占四分之一。去年第四季毛利率同比提升4.7个百分点至 90.5%，一般及行政费用费用率同比下降7.7百分点，non-GAAP净利润同比大增至2.25亿。公司指引 2026年收入62亿至64亿，GAAP经营费用47亿至49亿元，毛利率在80%区间的高位，non-GAAP净利润 14亿至15亿元，维持"买入"评级。 投行对该股的评级以买入为主，近90天内共有2家投行给出买入评级，近90天的目标均价为223.43港 元。国金证券最新一份研报给予百济神州买入评级。 机构评级详情见下表： 百济神州港股市值2741.47亿港元，在生物制品Ⅱ行业中排名第1。主要指标见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

正大企业国际港股市值16.1亿港元，在生物制品Ⅱ行业中排名第37。主要指标见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 正大企业国际(03839.HK)公布，自2026年2月24日起，公司董事长谢吉人先生已由公司非执行董事调任 为公司执行董事，原因为其将于集团担任执行职务;李绍祝先生因欲投入更多时间处理其其他个人事 务，已辞任公司执行董事及行政总裁(工业业务)，亦不再担任董事会薪酬委员会成员;Kobboon Srichai 女 士已获委任为公司非执行董事;现任公司执行董事马德寿先生已获委任为公司行政总裁及薪酬委员会成 员;随着马德寿先生获委任后，李绍庆先生不再担任公司行政总裁(生化业务)，惟其留任为公司执行董 事。 截至2026年2月24日收盘，正大企业国际(03839.HK)报收于6.68港元，下跌0.15%，成交量12.8万股，成 交额85.62万港元。投行对该股关注度不高，90天内无投行对其给出评级。 ...

Group 1 - The core viewpoint of the article is the strategic cooperation agreement signed between China National Pharmaceutical Group Beikong Biotechnology (08247.HK) and Guangdong Xiaoshou Medical Technology Co., Ltd. to enhance grassroots medical services and resource allocation [1] - The agreement aims to promote multi-dimensional collaboration in the grassroots healthcare sector, focusing on improving the quality of medical resources and service capabilities [1] - As of February 11, 2026, the stock price of China National Pharmaceutical Group Beikong Biotechnology closed at HKD 5.02, reflecting a 0.4% increase with a trading volume of 108,000 shares and a turnover of HKD 544,600 [1] Group 2 - The market capitalization of China National Pharmaceutical Group Beikong Biotechnology is HKD 321 million, ranking 47th in the biopharmaceutical II industry [1] - There has been low attention from investment banks regarding this stock, with no ratings provided in the past 90 days [1]

荣昌生物(09995.HK)发布公告，经公司财务部门初步测算，预计2025年度营业收入约人民币32.5亿元， 与上年同期相比，将增加收入约人民币15.33亿元，同比增加约89%。公司预计2025年度实现归属于母 公司所有者的净利润约人民币7.16亿元，与上年同期相比，实现扭亏为盈。公司预计2025年度归属于母 公司所有者扣除非经常性损益后的净利润约人民币7850万元，与上年同期相比，实现扭亏为盈。 截至2026年1月30日收盘，荣昌生物(09995.HK)报收于84.2港元，下跌0.41%，成交量281.42万股，成交 额2.38亿港元。投行对该股的评级以增持为主，近90天内共有4家投行给出增持评级，近90天的目标均 价为108.33港元。中泰国际最新一份研报给予荣昌生物买入评级，目标价114港元。 荣昌生物港股市值176.36亿港元，在生物制品Ⅱ行业中排名第8。主要指标见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 机构评级详情见下表： ...

诺诚健华(09969.HK)发布公告，于2025年1月1日至2025年12月31日。经财务部门初步测算，公司预计 2025年实现营业总收入人民币23.65亿元左右，与上年同期相比增长134%左右。公司预计2025年度首次 实现扭亏为盈。归属于母公司所有者的净利润为人民币6.33亿元左右，比上年同期归属于母公司所有者 的净利润增加人民币10.74亿元左右。公司预计2025年度归属于母公司所有者扣除非经常性损益后的净 利润为人民币5.34亿元左右，比上年同期增加人民币9.74亿元左右。 诺诚健华港股市值174.33亿港元，在生物制品Ⅱ行业中排名第9。主要指标见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年1月29日收盘，诺诚健华(09969.HK)报收于11.62港元，下跌0.43%，成交量357.89万股，成交 额4154.0万港元。投行对该股的评级以买入为主，近90天内共有3家投行给出买入评级，近90天的目标 均价为17.9港元。国元国际控股最新一份研报给予诺诚健华买入评级，目标价16.81港元。 机构评级详 ...

Group 1 - Morgan Stanley reported that the stock price of Innovent Biologics (01801.HK) fell by approximately 7% on Monday, which may be related to the recently announced National Reimbursement Drug List (NRDL) [1] - The investment bank maintains an "Overweight" rating on the stock, with nearly 12 investment firms issuing buy ratings in the past 90 days, and the average target price over this period is HKD 118.29 [1] - CITIC Securities recently provided a buy rating for Innovent Biologics with a target price of HKD 136.12 [1] Group 2 - Innovent Biologics has a market capitalization of HKD 147.301 billion and ranks second in the biopharmaceutical II industry [2]

Macro Strategy - The LPR remained unchanged in November, with the 1-year and 5-year rates at 3.00% and 3.50% respectively, indicating stable monetary policy despite weak macro data in October [2][3] - A-share indices experienced significant declines from November 17 to 21, with the Shanghai Composite Index down 3.90% and the ChiNext Index down 6.15%, primarily due to reduced expectations for a December rate cut by the Federal Reserve [3][4] - All primary industries in the A-share market declined, with energy metals and communication equipment showing the highest cumulative gains for 2025 at 83.18% and 78.97% respectively [5][6] Investment Recommendations - For the long term, 2026 is expected to be a year of growth driven by the "14th Five-Year Plan," with a stable A-share market anticipated [7] - Short-term strategies should focus on sectors benefiting from long-term capital inflows, traditional sectors related to "anti-involution," and consumer areas such as motorcycles and medical services [7] North Exchange Overview - As of November 21, 2025, the North Exchange had 284 listed stocks, with an average total market value of 864.16 billion yuan, a decrease of 4.16% from the previous week [10][11] - Notable new listings included Dapeng Industrial, which saw a 1211.11% increase in its stock price during its first week [10][12] Medical Services Industry - The pharmaceutical and biological sector fell by 6.88%, underperforming the Shanghai Composite Index by 3.11 percentage points [16][17] - The medical services sector's PE ratio is currently at 31.22, with a recent decline of 2.25 [18] - High-growth areas such as ADC and TIDES CDMO are recommended for investment, with companies like WuXi AppTec and WuXi Biologics highlighted [19][20][21] Automotive Industry - Yuanrong Qixing showcased 200,000 mass-produced vehicles at the Guangzhou Auto Show, aiming for a cumulative delivery of 1 million vehicles by 2026 [23][24] - The automotive sector is expected to benefit from the acceleration of intelligent technology adoption and supportive policies for vehicle consumption [25][26] - Investment opportunities are significant in the automotive and parts sectors, particularly for companies involved in smart components and electric vehicles [26][27]

Core Viewpoint - Fosun Pharma (02196.HK) announced a partnership agreement to establish a target fund with an investment of RMB 100 million, focusing on strategic emerging sectors such as chemical innovative drugs, biological drugs (including vaccines), high-end medical devices (including IVD), traditional Chinese medicine supplements, and synthetic biology [1]. Group 1: Company Investment and Market Performance - Fosun Pharma's subsidiary will participate as a limited partner (LP) in the target fund, which aims to invest in various strategic sectors [1]. - As of October 28, 2025, Fosun Pharma's stock closed at HKD 23.0, down 2.79%, with a trading volume of 5.34 million shares and a turnover of HKD 123 million [1]. - The stock has a market capitalization of HKD 12.799 billion, ranking 13th in the biopharmaceutical II industry [2]. Group 2: Analyst Ratings and Financial Metrics - The majority of investment banks have a "Buy" rating for Fosun Pharma, with one bank issuing a "Buy" rating in the last 90 days and a target price of HKD 23.2 [1]. - Key financial metrics for Fosun Pharma compared to the biopharmaceutical II industry average include: - ROE: 6.89% (Industry Average: 10.46%, Ranking: 15th) - Revenue: HKD 39.952 billion (Industry Average: HKD 2.54 billion, Ranking: 1st) - Net Profit Margin: 10.81% (Industry Average: -381.46%, Ranking: 14th) - Gross Margin: 47.89% (Industry Average: 59.38%, Ranking: 32nd) - Debt Ratio: 49.26% (Industry Average: 74.41%, Ranking: 33rd) [2].

Macro Strategy - In September, CPI decreased by 0.3% year-on-year and increased by 0.1% month-on-month, with food prices rising by 0.7% and pork prices falling by 17.0%, contributing to a 0.26 percentage point decline in CPI [2][4] - By the end of September, M2 balance reached 335.38 trillion yuan, growing by 8.4% year-on-year, while the total social financing stock was 437.08 trillion yuan, up 8.7% year-on-year [2][4] Healthcare Services Industry - The pharmaceutical and biological sector fell by 1.20%, ranking 25th among 31 primary industries, with the medical services sub-sector dropping 3.37% [6][9] - WuXi AppTec is highlighted as a CRDMO integrated platform company, with its R&D segment driving growth and D&M capacity release significantly increasing revenue per capita from 542,000 yuan in 2018 to an expected 1,118,000 yuan in 2025 [7][8] - The long-term development trend of the healthcare services industry remains positive despite recent geopolitical tensions, with a "buy" rating maintained for the sector [9] Securities Industry - The securities sector showed active performance post-holiday, with the brokerage index rising by 0.5%, outperforming the CSI 300 index by 1 percentage point [11][15] - Daily average stock trading volume reached 25.87 trillion yuan, a 19% increase from the previous period, indicating a significant recovery in trading activity [12][13] - The investment recommendation for the securities industry is to maintain an "overweight" rating, focusing on internet brokerages and firms with strong performance certainty [15] Electronic Industry - OpenAI's release of Sora 2.0 marks a significant milestone in AI applications, with the new video generation model achieving high realism and user engagement [17][19] - The electronic industry is expected to benefit from ongoing recovery in consumer electronics and AI technology advancements, maintaining an "overweight" rating [19] New Materials Industry - The rare earth magnetic materials sector increased by 10.44%, outperforming the benchmark by 8.97 percentage points, while rare earth prices showed mixed trends [21][24] - The investment outlook remains cautious, with a recommendation to maintain an "overweight" rating, focusing on upstream rare earth resource companies and downstream magnetic material firms [25] Banking Industry - Social financing growth slowed to 8.7% in September, with improvements in credit structure, particularly in long-term loans supported by policy measures [28][32] - The banking sector is expected to maintain stable performance, with a recommendation to focus on state-owned banks and regional banks for their investment value [32]

Core Viewpoint - 招银国际's report indicates that 复宏汉霖 (02696.HK) achieved a 3% year-on-year revenue increase to 2.82 billion RMB in the first half of the year, aligning with expectations, with drug sales reaching 2.57 billion RMB, representing 49% of the annual forecast [1] Financial Performance - Revenue for 复宏汉霖 in the first half of the year was 2.82 billion RMB, with drug sales contributing 2.57 billion RMB [1] - Net profit increased by 1% year-on-year to 390 million RMB, achieving 31% of the annual forecast [1] Market Position and Valuation - 招银国际 raised the target price for 复宏汉霖 from 61.98 HKD to 97.75 HKD, maintaining a "buy" rating [1] - The stock closed at 74.0 HKD, down 6.51%, with a trading volume of 2.5164 million shares and a turnover of 191 million HKD [1] - The market capitalization of 复宏汉霖 is 12.935 billion HKD, ranking 15th in the biopharmaceutical II industry [2] Analyst Ratings - Recent ratings from various investment banks include: - 国投证券: Buy, target price 93.45 HKD [1] - CMB International Capital: Buy, target price 97.75 HKD [1] - 中金公司: Outperform, target price 102.91 HKD [1] - 天风证券: Buy, target price 78.01 HKD [1] - 申万宏源: Buy, target price 71.00 HKD [1] Key Financial Metrics - 复宏汉霖's return on equity (ROE) is 27.33%, significantly higher than the industry average of -12.33% [2] - The company's net profit margin stands at 13.84%, compared to the industry's -555.02% [2] - Gross margin for 复宏汉霖 is 78.0%, while the industry average is 59.87% [2] - The company's debt ratio is 70.49%, lower than the industry average of 83.88% [2]